| Literature DB >> 24650860 |
Daniela N Schulz1, Eline S Smit, Nicola E Stanczyk, Stef P J Kremers, Hein de Vries, Silvia M A A Evers.
Abstract
BACKGROUND: Different studies have reported the effectiveness of Web-based computer-tailored lifestyle interventions, but economic evaluations of these interventions are scarce.Entities:
Keywords: Internet interventions; Web-based; computer-tailoring; cost-effectiveness; cost-utility; economic evaluation; lifestyle behaviors; randomized controlled trial
Mesh:
Year: 2014 PMID: 24650860 PMCID: PMC3978559 DOI: 10.2196/jmir.3159
Source DB: PubMed Journal: J Med Internet Res ISSN: 1438-8871 Impact factor: 5.428
Figure 1Flow diagram of the economic study.
Figure 2Design of the study. HRA: health risk appraisal.
Comparability of the 3 study groups regarding demographics, health status, lifestyle behavior, and health care and travel costs over the past 3 months before baseline (N=1733)
| Variable | Sequential | Simultaneous | Control |
| χ2 ( |
| |
| Age, mean (SD) | 47.31 (11.62) | 48.15 (11.96) | 48.88 (12.19) | 2.61 (2, 1730) |
| .07 | |
|
|
|
|
|
|
|
| |
|
| Men | 279 (50.5) | 264 (51.1) | 366 (55.1) |
|
|
|
|
| Women | 273 (49.5) | 253 (48.9) | 298 (44.9) |
| 3.1 (2) | .21 |
|
|
|
|
|
|
|
| |
|
| Low | 53 (9.9) | 64 (12.9) | 90 (13.7) |
|
|
|
|
| Medium | 274 (51.3) | 222 (44.7) | 319 (48.7) |
|
|
|
|
| High | 207 (38.8) | 211 (42.5) | 246 (37.6) |
| 7.9 (4) | .10 |
|
|
|
|
|
|
|
| |
|
| < 1,750 | 123 (22.9) | 123 (24.7) | 161 (24.5) |
|
|
|
|
| 1750 - 3050 | 265 (49.3) | 249 (50.0) | 341 (52.0) |
|
|
|
|
| > 3050 | 150 (27.9) | 126 (25.3) | 154 (23.5) |
| 3.2 (4) | .52 |
|
|
|
|
|
|
|
| |
|
| Job (paid) | 389 (72.2) | 350 (70.3) | 443 (67.4) |
|
|
|
|
| No job | 150 (27.8) | 148 (29.7) | 214 (32.6) |
| 3.2 (2) | .20 |
|
|
|
|
|
|
|
| |
|
| Relationship | 423 (78.9) | 402 (80.2) | 507 (77.4) |
|
|
|
|
| Single | 113 (21.1) | 99 (19.8) | 148 (22.6) |
| 1.4 (2) | .50 |
| Persons in household, mean (SD) | 2.83 (1.65) | 2.69 (1.24) | 2.71 (1.37) | 1.54 (2, 1695) |
| .21 | |
|
|
|
|
|
|
|
| |
|
| The Netherlands | 511 (95.0) | 480 (96.0) | 627 (95.3) |
|
|
|
|
| Other | 27 (5.0) | 20 (4.0) | 31 (4.7) |
| 0.6 (2) | .73 |
| BMI, mean (SD) | 25.70 (4.18) | 25.38 (3.91) | 25.80 (5.71) | 1.56 (2, 1714) |
| .21 | |
| Psychological distress, mean (SD) | 44.46 (6.40) | 45.00 (5.84) | 44.74 (6.10) | 1.00 (2, 1687) |
| .37 | |
|
|
|
|
|
|
|
| |
|
| Diabetes | 25 (4.7) | 20 (4.0) | 23 (3.5) |
| 1.0 (2) | .61 |
|
| Brain hemorrhage, TIA | 2 (0.4) | 4 (0.8) | 7 (1.1) |
| 1.9 (2) | .38 |
|
| Heart attack | 8 (1.5) | 5 (1.0) | 5 (0.8) |
| 1.5 (2) | .48 |
|
| Other serious heart disease | 4 (0.7) | 12 (2.4) | 15 (2.3) |
| 5.2 (2) | .07 |
|
| Cancer | 12 (2.2) | 7 (1.4) | 11 (1.7) |
| 1.1 (2) | .58 |
|
| High blood pressure | 67 (12.5) | 67 (13.4) | 112 (17.2) |
| 6.0 (2) | .05 |
|
| Asthma, COPD | 36 (6.7) | 34 (6.8) | 43 (6.6) |
| 0.01 (2) | .99 |
| Lifestyle factor, mean (SD) | 3.26 (1.04) | 3.32 (1.07) | 3.27 (1.06) | 0.52 (2, 1730) |
| .59 | |
| Euroqol/utility (EQ-5D-3L), mean (SD) | 0.89 (0.17) | 0.89 (0.15) | 0.90 (0.15) | 0.40 (2, 1617) |
| .67 | |
|
|
|
|
|
|
|
| |
|
| Medication use | 44.62 (256.77) | 39.14 (313.81) | 31.68 (204.78) | 0.39 (2, 1725) |
| .68 |
|
| Health care service | 119.12 (401.90) | 114.42 (201.50) | 99.16 (184.52) | 0.88 (2, 1729) |
| .42 |
|
| Admissions | 32.95 (231.26) | 31.98 (222.70) | 62.85 (422.57) | 1.88 (2, 1728) |
| .15 |
|
| Other care | 34.04 (220.28) | 21.28 (157.88) | 40.41 (265.29) | 1.08 (2, 1728) |
| .34 |
| Absenteeism from work | 676.68 (3135.31) | 405.10 (2076.48) | 328.19 (1413.07) | 3.63 (2, 1674) |
| .03 | |
| Travel costs (€), mean (SD) | 3.20 (10.42) | 3.46 (6.41) | 2.97 (5.63) | 0.54 (2, 1579) |
| .59 | |
aRespondents who did not want to report their income (n=257) were classified in the category €1751-€3050.
bTIA: transient ischemic attack; COPD: chronic obstructive pulmonary disease.
cCosts for prior 3 months.
Mean biennial costs per participant per study group based on 5000 bootstrap replications.
| Cost type | Costs per study group (€), mean (SD) | 95% CI | |||||
|
| Sequential | Simultaneous | Control | Sequential-Simultaneous | Control-Simultaneous | Sequential-Control | |
|
|
|
|
|
|
|
| |
|
| Fixed hosting costs | 0.54 | 0.54 | 0.54 |
|
|
|
|
|
|
|
|
|
|
| |
|
| Medication use (n=1733) | 193 (57) | 200 (74) | 162 (31) | -208.73, 166.37 | -222.27, 91.00 | -81.95, 175.03 |
|
| Health care service (n=1733) | 719 (124) | 861 (73) | 641 (42) | -385.33, 169.11 | -386.86, -56.07 | -131.59, 368.62 |
|
| Admissions (n=1732) | 396 (89) | 303 (78) | 461 (97) | -141.58, 325.48 | -87.86, 401.07 | -327.51, 200.20 |
|
| Other care (n=1732) | 222 (67) | 178 (40) | 247 (67) | -97.69, 204.61 | -76.51, 230.00 | -211.27, 161.91 |
|
| Total health care costs (n=1714) | 1521 (195) | 1534 (162) | 1502 (151) | -508.11, 504.92 | -461.19, 399.62 | -453.30, 493.35 |
|
|
|
|
|
|
|
| |
|
| Absenteeism (n=1714) | 3489 (652) | 3563 (666) | 2600 (538) | -1889.89, 1751.48 | -2642.42, 673.86 | -724.22, 2586.62 |
|
|
|
|
|
|
|
| |
|
| Travel costs (n=1678) | 25 (3) | 30 (3) | 24 (2) | -13.26, 3.42 | -12.55, -0.41 | -5.40, 9.10 |
|
| Fixed time costs (n=1733) | 41 (0) | 59 (1) | 12 (0) | -18.65, -16.27 | -47.71, -45.71 | 28.53, 29.95 |
|
| Total respondent costs (n=1678) | 64 (3) | 87 (3) | 35 (2) | -30.66, -13.28 | -57.81, -45.39 | 22.25, 37.19 |
Mean biennial effect on the lifestyle factor score (LFS) and quality-adjusted life year (QALY) score per participant per study group.
| Effect | Mean (SD) per study group |
|
| ||
|
| Sequential | Simultaneous | Control |
|
|
| LFSa (n=1733) | 3.37 (1.08) | 3.42 (1.06) | 3.34 (1.05) | 0.92 (2, 1730) | .40 |
| QALY (EQ-5D-3L) (n=1690) | 1.80 (0.30) | 1.78 (0.31) | 1.82 (0.27) | 1.79 (2, 1687) | .17 |
aThis factor could range from 0 (adherence to all guidelines) to 5 (adherence to no guideline at all), plus discounting effect.
Incremental costs and effects per gain in lifestyle factor score (LFS) and per quality-adjusted life year (QALY) gained for the study groups with a willingness-to-pay threshold of €18,000.
| Intervention | Incremental costs (€)a | Incremental effectb | Incremental costs per LFS/QALY (€) | |
|
|
|
|
| |
|
| Sequential vs control | 183.76 | .04 | 4594.00 |
|
| Simultaneous vs control | 868.00 | .08 | 10,850.00 |
|
| Sequential vs simultaneous | –684.24 | –.04 | 17,106.00 |
|
|
|
|
| |
|
| Sequential vs control | 183.76 | –.01 | Dominatedc |
|
| Simultaneous vs control | 868.00 | –.03 | Dominatedc |
|
| Sequential vs simultaneous | –684.24 | .02 | Dominatedc |
aCosts per participant (€): sequential=4324.76; simultaneous=5009.00; control=4141.00.
bLifestyle factor effects per participant: sequential=3.38, simultaneous=3.42, control=3.34; QALYs effects per participant: sequential=1.80, simultaneous=1.78, control=1.81.
cIn one group, the costs are higher and the effects are lower compared to the other group.
Results from cost-effectiveness and cost-utility analyses based on 1000 bootstrap replications for the sequential (seq), simultaneous (sim), and control (con) conditions.
| Type of analysis | Study group (n) | Probability of highest net monetary benefit (%) | |||||||||||
|
| Seq | Sim | Con | WTP=€0 | WTP=€18,000 | WTP=€80,000 | |||||||
|
|
|
|
| Seq | Sim | Con | Seq | Sim | Con | Seq | Sim | Con | |
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
| LFS | 552 | 517 | 664 | 42 | 10 | 48 | 39 | 45 | 16 | 26 | 68 | 6 |
|
| QALY (EQ-5D-3L) | 535 | 501 | 654 | 39 | 12 | 49 | 21 | 4 | 76 | 7 | 1 | 92 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
| Only health care costs included | 552 | 517 | 664 | 38 | 27 | 35 | 24 | 70 | 6 | 24 | 71 | 6 |
|
| Productivity costs Excluded | 552 | 517 | 664 | 59 | 20 | 21 | 22 | 71 | 7 | 20 | 73 | 7 |
|
| ≥ 50% of follow-up questionnaires completed | 100 | 104 | 195 | 3 | 29 | 68 | 14 | 83 | 2 | 20 | 80 | 0 |
|
| LFCI to correct for baseline scores | 552 | 517 | 664 | 45 | 11 | 45 | 65 | 15 | 20 | 63 | 27 | 10 |
|
| Respondents with outliers on total costs excludeda | 525 | 488 | 637 | 81 | 11 | 8 | 25 | 69 | 6 | 22 | 72 | 6 |
|
| Without discounting costs and effects | 552 | 517 | 664 | 41 | 11 | 48 | 37 | 45 | 18 | 26 | 66 | 8 |
|
| Discounting costs and effects 2nd year with 4.0% | 552 | 517 | 664 | 43 | 11 | 46 | 39 | 45 | 16 | 27 | 66 | 7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
| Only health care costs included | 535 | 501 | 654 | 31 | 32 | 38 | 10 | 3 | 87 | 7 | 1 | 92 |
|
| Productivity costs excluded | 535 | 501 | 654 | 56 | 19 | 25 | 14 | 2 | 84 | 7 | 1 | 93 |
|
| ≥ 50% of follow-up questionnaires completed | 100 | 104 | 195 | 6 | 25 | 70 | 5 | 21 | 74 | 7 | 21 | 73 |
|
| QALY corrected for baseline as outcome variable | 513 | 482 | 621 | 38 | 18 | 43 | 36 | 13 | 51 | 29 | 8 | 63 |
|
| Respondents with outliers on total costs excludeda | 509 | 475 | 627 | 80 | 9 | 11 | 25 | 3 | 73 | 13 | 2 | 85 |
|
| Without discounting costs and effects | 535 | 501 | 654 | 38 | 12 | 50 | 22 | 4 | 75 | 8 | 1 | 91 |
|
| Discounting costs and effects 2nd year with 4.0% | 535 | 501 | 654 | 40 | 12 | 48 | 22 | 4 | 75 | 7 | 1 | 92 |
aBased on the 95th percentile: €18,567.64.
Figure 3Cost-effectiveness acceptability curve for the study groups based on primary and sensitivity analyses.
Figure 4Cost-utility acceptability curves for the study groups based on primary and sensitivity analyses.